Brain metabolite profiles of T1-hypointense lesions in relapsing-remitting multiple sclerosis.

BACKGROUND AND PURPOSE Persistent T1-hypointense lesions ("black holes") are thought to represent permanent damage of brain parenchyma. We attempted to ascertain whether the metabolic profiles of these hypointense areas support this hypothesis and whether these profiles correlate with these hypointense findings. METHODS Four patients with relapsing-remitting multiple sclerosis and four matched control volunteers underwent MR imaging and 3D proton MR spectroscopy. Absolute levels of N-acetylaspartate (NAA), creatine, and choline (Cho) were obtained in 0.19 cm(3) voxels containing 14 T1-hypointense lesions (average volume, 0.4 cm(3); range, 0.2-1.0 cm(3)) in patients. Metabolite levels were analyzed, by using Pearson correlation, against their respective lesions' hypointensity relative to the surrounding normal-appearing white matter. RESULTS Moderate correlation, r = 0.56, was found between the NAA level and MR imaging hypointensity. Of the 14 lesions studied, 12 were deficient in NAA and 11 had excess Cho compared with corresponding brain regions in control volunteers. Only one lesion was significantly deficient in all three metabolites, indicative of total damage or matrix loss. CONCLUSION No relationship was found between the hypointensity of the lesions and their metabolic profile. Specifically, lesions with the same hypointensity on T1-weighted MR images were metabolically variable (ie, displayed disparate metabolite levels and behavior). Also, although 86% of the lesions exhibited abnormally low NAA, 71% also had increased Cho. This indicates that although neuronal damage had already occurred (lower NAA), these lesions were still "smoldering" with active membrane turnover (high Cho), most likely because of de- and remyelination, indicative of shadow plaques (remyelinated lesions). Consequently, relapsing-remitting hypointense lesions represent neither final-stage nor static pathologic abnormality.

[1]  F. Barkhof,et al.  Axonal loss in multiple sclerosis lesions: Magnetic resonance imaging insights into substrates of disability , 1999, Annals of neurology.

[2]  C. Lucchinetti,et al.  Remyelination in multiple sclerosis , 1997, Multiple sclerosis.

[3]  F Barkhof,et al.  Neuronal damage in T1‐hypointense multiple sclerosis lesions demonstrated in vivo using proton magnetic resonance spectroscopy , 1999, Annals of neurology.

[4]  R I Grossman,et al.  Perspectives on multiple sclerosis. , 1998, AJNR. American journal of neuroradiology.

[5]  J S Taylor,et al.  Chemical shift imaging of human brain: axial, sagittal, and coronal P-31 metabolite images. , 1990, Radiology.

[6]  D. Gadian,et al.  Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[7]  G. Barker,et al.  Lesion heterogeneity in multiple sclerosis: a study of the relations between appearances on T1 weighted images, T1 relaxation times, and metabolite concentrations , 2000, Journal of neurology, neurosurgery, and psychiatry.

[8]  F. Barkhof,et al.  Patterns of lesion development in multiple sclerosis: longitudinal observations with T1-weighted spin-echo and magnetization transfer MR. , 1998, AJNR. American journal of neuroradiology.

[9]  P. Matthews,et al.  The use of magnetic resonance spectroscopy in the evaluation of the natural history of multiple sclerosis. , 1998, Journal of neurology, neurosurgery, and psychiatry.

[10]  H. Larsson,et al.  The concentration of N-acetyl aspartate, creatine + phosphocreatine, and choline in different parts of the brain in adulthood and senium. , 1993, Magnetic resonance imaging.

[11]  F Barkhof,et al.  The role of MRI as a surrogate outcome measure in multiple sclerosis , 2002, Multiple sclerosis.

[12]  J K Udupa,et al.  Relapsing-remitting multiple sclerosis: longitudinal analysis of MR images--lack of correlation between changes in T2 lesion volume and clinical findings. , 1999, Radiology.

[13]  Alan J. Thompson,et al.  Disability and lesion load in MS: a reassessment with MS functional composite score and 3D fast FLAIR , 2002, Journal of Neurology.

[14]  Oded Gonen,et al.  Reproducibility of 3D proton spectroscopy in the human brain , 2002, Magnetic resonance in medicine.

[15]  F. Barkhof,et al.  Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis , 1998, Neurology.

[16]  H. Tobi,et al.  Correlating MRI and clinical disease activity in multiple sclerosis , 1995, Neurology.

[17]  J. Duyn,et al.  Quantitative proton MR spectroscopic imaging of the human brain , 1996, Magnetic resonance in medicine.

[18]  F Barkhof,et al.  T1 hypointensities and axonal loss. , 2000, Neuroimaging clinics of North America.

[19]  W Steinbrich,et al.  Serial proton MR spectroscopy of contrast-enhancing multiple sclerosis plaques: absolute metabolic values over 2 years during a clinical pharmacological study. , 2000, AJNR. American journal of neuroradiology.

[20]  B. Weinshenker,et al.  Natural history of multiple sclerosis. , 2005, Neurologic clinics.

[21]  G J Barker,et al.  Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. , 1994, Brain : a journal of neurology.

[22]  M Cercignani,et al.  Diffusion tensor magnetic resonance imaging in multiple sclerosis , 2001, Neurology.

[23]  R Stoyanova,et al.  3D multivoxel proton spectroscopy of human brain using a hybrid of 8th‐order hadamard encoding with 2D chemical shift imaging , 1998, Magnetic resonance in medicine.

[24]  J. Cumings,et al.  Biochemistry and the Central Nervous System , 1967, Neurology.

[25]  J. Simon.  Contrast‐enhanced MR imaging in the evaluation of treatment response and prediction of outcome in multiple sclerosis , 1997, Journal of magnetic resonance imaging : JMRI.

[26]  S. Sehlen,et al.  The value of T1-weighted images in the differentiation between MS, white matter lesions, and subcortical arteriosclerotic encephalopathy (SAE) , 2004, Neuroradiology.

[27]  Ad Bax,et al.  Improved solvent suppression in one-and two-dimensional NMR spectra by convolution of time-domain data , 1989 .

[28]  F. Barkhof,et al.  Characterization of tissue damage in multiple sclerosis by nuclear magnetic resonance. , 1999, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[29]  Remyelination in multiple sclerosis , 1979, Annals of neurology.

[30]  O Henriksen,et al.  In vivo quantitation of metabolite concentrations in the brain by means of proton MRS , 1995, NMR in biomedicine.

[31]  B D Ross,et al.  Absolute Quantitation of Water and Metabolites in the Human Brain. II. Metabolite Concentrations , 1993 .

[32]  G J Barker,et al.  The proton NMR spectrum in acute EAE: The significance of the change in the Cho:Cr ratio , 1993, Magnetic resonance in medicine.

[33]  J H Simon,et al.  A longitudinal study of T1 hypointense lesions in relapsing MS , 2000, Neurology.

[34]  P M Matthews,et al.  Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques , 1992, Annals of neurology.

[35]  V. Govindaraju,et al.  Automated spectral analysis III: Application to in Vivo proton MR Spectroscopy and spectroscopic imaging , 1998, Magnetic resonance in medicine.

[36]  T R Brown,et al.  A fast, reliable, automatic shimming procedure using 1H chemical-shift-imaging spectroscopy. , 1995, Journal of magnetic resonance. Series B.

[37]  F. Barkhof,et al.  Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis , 1996, Neurology.

[38]  C. Lucchinetti,et al.  A longitudinal MRI study of histopathologically defined hypointense multiple sclerosis lesions , 2001, Annals of neurology.

[39]  B J Soher,et al.  Representation of strong baseline contributions in 1H MR spectra , 2001, Magnetic resonance in medicine.

[40]  G. Fein,et al.  Biochemical alterations in multiple sclerosis lesions and normal‐appearing white matter detected by in vivo 31P and 1H spectroscopic imaging , 1994, Annals of neurology.

[41]  R. Grossman,et al.  Magnetization transfer effects in MR-detected multiple sclerosis lesions: comparison with gadolinium-enhanced spin-echo images and nonenhanced T1-weighted images. , 1995, AJNR. American journal of neuroradiology.

[42]  Christopher M. Dobson,et al.  Resolution enhancement of protein PMR spectra using the difference between a broadened and a normal spectrum , 1973 .

[43]  P M Matthews,et al.  Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. , 2001, Archives of neurology.

[44]  B. Miller.  A review of chemical issues in 1H NMR spectroscopy: N‐acetyl‐l‐aspartate, creatine and choline , 1991, NMR in biomedicine.

[45]  R I Grossman,et al.  Characterization of multiple sclerosis plaques with T1-weighted MR and quantitative magnetization transfer. , 1995, AJNR. American journal of neuroradiology.